Status:
UNKNOWN
Effect of Oral Isotretinoin on The Level of SerumYKL40 in Acne Vulgaris Patients
Lead Sponsor:
Alshimaa Abbas Mohamed Ebrahim
Conditions:
Acne Vulgaris
Eligibility:
All Genders
15-60 years
Phase:
PHASE4
Brief Summary
The aim of the study is to evaluate the effect of oral isotretinoin on SerumYKL40 in acne vulgaris patients.
Detailed Description
Acne vulgaris is a common chronic inflammatory disease of the skin. It is found in about 80% of young adults and adolescents. It is a disease that affects the pilosebaceous units of the skin and may r...
Eligibility Criteria
Inclusion
- Healthy persons of both sexes with moderate and severe acne.
- Age above 14 years.
Exclusion
- Pregnant and lactating women, immunocompromised patients.
- History of chronic liver disease, hyperlipidemia, non-inflammatory acne conditions, , history of neurologic disorders, history of neoplastic disorders, and history of cardiac disease.
- History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.
- Cases with known hypersensitivity reaction to isotretinoin.
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05218486
Start Date
August 1 2021
End Date
September 30 2022
Last Update
September 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan university
Aswān, Egypt, 81528